A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Clinical trial NCT05171647 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05171647
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-25
- Primary completion
- 2025-02-17
- Enrollment
- 208
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.